tenofovir has been researched along with bictegravir in 74 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 20 (27.03) | 24.3611 |
2020's | 54 (72.97) | 2.80 |
Authors | Studies |
---|---|
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K | 1 |
Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D | 1 |
Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K | 1 |
Jones, J; Taylor, BS; Tieu, HV; Wilkin, TJ | 1 |
Castagna, A; Lazzarin, A; Spagnuolo, V | 1 |
Harris, M | 1 |
Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P | 1 |
Clarke, A; Garner, W; Laouri, M; Maggiolo, F; Martin, H; Quirk, E; Wohl, D | 1 |
Byland, E; Canupp, K; Dunlap, J; Mospan, C; Mospan, G; Whitaker, WB; Xiong, L | 1 |
Mesplède, T; Pham, HT | 1 |
Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M | 1 |
Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y | 1 |
Barber, TJ | 1 |
Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X | 1 |
Andreatta, K; Chang, S; Graham, H; Liu, H; Liu, YP; Martin, H; Martin, R; Quirk, E; Wei, L; White, KL; Willkom, M | 1 |
Acosta, RK; Avihingsanon, A; Cao, H; Chetchotisakd, P; DeJesus, E; Gankina, N; Hagins, D; Kityo, C; Koenig, E; Makadzange, T; Martin, H; Pokrovsky, V; Quirk, E; Stephens, JL; Supparatpinyo, K; Voronin, E; Wang, H | 1 |
Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J | 1 |
Di Perri, G | 1 |
Álvarez, M; Chueca, N; Collado, A; de Salazar, A; Fernández, JM; Fernández-Fuertes, E; García, F; Lozano, AB | 1 |
Badowski, ME; Biagi, MJ; Chiampas, TD; Michienzi, SM; Patel, MC; Schriever, CA; Young, JD | 1 |
Adam, A; Buhk, T; Fenske, S; Hansen, S; Hoffmann, C; Sabranski, M; Schewe, K; Stellbrink, HJ | 1 |
André-Garnier, E; Charpentier, C; Ferré, V; Hingrat, QL; Leducq, V; Malet, I; Marcelin, AG; Peytavin, G; Raffi, F; Reliquet, V; Rodallec, A | 1 |
Hill, A; Venter, WDF | 1 |
Acosta, R; Brainard, DM; Collins, SE; Liu, H; Luetkemeyer, AF; Martin, H; Rieger, A; Rockstroh, JK; Sax, PE; Trottier, B; Ward, D; Yazdanpanah, Y | 1 |
Bremner, S; Bruce, C; Churchill, D; Geretti, AM; Iwuji, CC; Lambert, D; Orkin, C; Perry, N; To, Y; Waters, L | 1 |
Acosta, RK; Andreatta, K; Collins, S; Liu, H; Martin, H; Martin, R; Parvangada, A; White, KL; Willkom, M | 1 |
Alonso-Vega, GG; Ferrández, JS; García, AL; García, TM; González, AO | 1 |
Chivite, I; Cottrell, ML; Domingo, P; Garcia, B; Imaz, A; Kashuba, ADM; Martinez-Picado, J; Morenilla, S; Negredo, E; Niubó, J; Podzamczer, D; Scévola, S; Schauer, A; Silva-Klug, A; Tiraboschi, JM; Urrea, V; Van Horne, B | 1 |
Babusis, D; Barouch, DH; Bekerman, E; Callebaut, C; Campigotto, F; Cihlar, T; Cox, S; Das, M | 1 |
Acosta, RK; Brainard, D; Chang, S; Chen, GQ; Collins, SE; Huang, H; Martin, H; Martin, R; Wang, X; White, KL | 1 |
Gutiérrez-Lorenzo, M; Rubio-Calvo, D; Urda-Romacho, J | 1 |
Alrubayyi, A; Burns, F; Fisher-Pearson, N; Gilson, R; Griffith, SA; Gupta, RK; Kinloch, S; McCoy, LE; Muir, L; Pellegrino, P; Peppa, D; Rees-Spear, C; Rowland-Jones, S; Touizer, E; Waters, L | 1 |
Bachelard, A; Chalal, L; Damond, F; Descamps, D; Ghosn, J; Isernia, V; Landman, R; Le Gac, S; Peytavin, G; Vallois, D; Yazdanpanah, Y | 1 |
Bamoulid, J; Clairet, AL; Davani, S; Ducloux, D; Flammang, M; Lagoutte-Renosi, J; Lepiller, Q; Muret, P; Royer, PY | 1 |
Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E | 1 |
Andreatta, K; Berger, D; Blair, C; Brainard, DM; Brar, I; Collins, SE; Hagins, D; Hileman, CO; Kumar, P; Martin, H; McDonald, C; Osiyemi, O; Ramgopal, MN; Saag, M; Wurapa, AK | 1 |
Agrati, C; Antinori, A; Cicalini, S; D'Avolio, A; De Nicolò, A; Tempestilli, M | 1 |
Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K | 1 |
Barrail-Tran, A; Becker, PH; Castro Gordon, A; Catalan, P; Chéret, A; Furlan, V; Gasnault, J; Gelé, T; Gouget, H; Goujard, C; Nkam, L; Pallier, C; Taburet, AM | 1 |
Bazzi, R; Roa, PE | 1 |
Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY | 1 |
Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
Acosta, R; Andreatta, K; Chang, S; D'Antoni, ML; Martin, H; Martin, R; White, KL | 1 |
Gelman, M; Holmes, J; Kraft, J; Mayer, KH; Melbourne, K; Mimiaga, MJ | 1 |
Ambrosioni, J; Berrocal, L; Blanco, JL; Chivite, I; de la Mora, L; de Lazzari, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; Mallolas, J; Martinez, E; Martínez-Rebollar, M; Miró, JM; Rojas Liévano, J; Torres, B; Ugarte, A | 1 |
Blanco, JR; Calzado Isbert, S; López Cortés, LF; Martínez-Sanz, J; Mena, Á; Moreno, E; Moreno, S; Muriel, A; Pineda, JA; Ron, R; Sánchez-Conde, M; Serrano-Villar, S | 1 |
Acosta, R; Andreatta, K; Blair, C; Chang, S; Collins, SE; D'Antoni, ML; Daar, ES; Gallant, J; Hagins, D; Liu, H; Martin, H; Martin, R; McNicholl, I; Molina, JM; Sax, PE; White, KL | 1 |
Alessandri-Gradt, E; Martin, C; Plantier, JC; Unal, G | 1 |
Bookstaver, PB; Clary, JC; Derrick, C; Drummond, M; Rowe, SM; Sanasi, K | 1 |
Berenguer, J; Blair, C; Chuck, SK; D'Antoni, ML; De Wit, S; Gallant, J; Haubrich, R; Maggiolo, F; Martin, H; McNicholl, IR; Molina, JM; Piontkowsky, D; Pulido, F; Rizzardini, G; Vandekerckhove, L | 1 |
Bernardino, JI; de Gea Grela, A; Martín Carbonero, L; Micán, R; Ramos, L; Valencia, ME | 1 |
Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY | 1 |
Andreoni, M; Antinori, A; Armenia, D; Berno, G; Bertoli, A; Borghi, V; Buonomini, A; Ceccherini-Silberstein, F; Cicalini, S; Forbici, F; Gagliardini, R; Gennari, W; Lanini, S; Latini, A; Malagnino, V; Mussini, C; Perno, CF; Santoro, MM; Sarmati, L; Teti, E | 1 |
Arribas, JR; Bernardino, JI; Busca, C; Cadiñanos, J; de Gea Grela, A; de Miguel, R; González-García, J; Martín-Carbonero, L; Micán, R; Montejano, R; Montes, ML; Moreno, V; Pérez Valero, I; Serrano, L; Valencia, E | 1 |
Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y | 1 |
Derkach, EV; Pyadushkina, EA | 1 |
Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C | 1 |
Johnson, TM; Rivera, CG | 1 |
Chen, CP; Hung, CC; Hung, TC; Lee, CH; Lee, CY; Lee, YT; Li, CW; Liou, BH; Liu, CE; Sun, HY; Tang, HJ; Tsai, MS; Yang, CJ | 1 |
Baldi, A; Carleo, MA; Contieri, M; De Blasiis, P; De Luca, A; Esposito, V; Guerra, G; Guida, A; Hay, E; Lucariello, A; Maggi, P; Mascolo, S; Perna, A; Sellitto, C | 1 |
Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA | 1 |
Chang, HY; Chen, LY; Chuang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Su, YC; Sun, HY; Wu, PY | 1 |
Fang, Z; Gang, X; Guoqiang, Z; Jing, C; Min, W; Ning, W; Wei, T; Xingzhi, W | 1 |
Brumme, CJ; DeKoven, S; Naccarato, M; Tan, DHS | 1 |
Álvarez-Díaz, AM; Esteban-Cartelle, B; Gramage-Caro, T; Montero-Llorente, B; Parro-Martín, MLÁ; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M | 1 |
Ishikawa, K; Kawai, F; Mori, N | 1 |
Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F | 1 |
Erk, N; Genc, AA; Oven, E; Tiris, G | 1 |
De Clercq, E; Huang, J; Li, G; Zhang, M; Zhang, Z | 1 |
Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B | 1 |
Cao, X; Peng, Y; Wang, M; Wang, Y; Yu, W; Zeng, Z | 1 |
7 review(s) available for tenofovir and bictegravir
Article | Year |
---|---|
Bictegravir.
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2018 |
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Drug Combinations; Drug Interactions; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir | 2019 |
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Topics: Adenine; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Tenofovir | 2019 |
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir | 2019 |
Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Viral Load | 2022 |
Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review.
Topics: Anti-HIV Agents; Cerebral Infarction; Drug Combinations; Emtricitabine; Herpesvirus 3, Human; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2023 |
Biktarvy for the treatment of HIV infection: Progress and prospects.
Topics: Adenine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Pyridones; Tenofovir | 2023 |
21 trial(s) available for tenofovir and bictegravir
Article | Year |
---|---|
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
Topics: Adenine; Adult; Aged; Alanine; Amides; Anti-Retroviral Agents; Drug Substitution; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Protease Inhibitors; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; Europe; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; United States; Young Adult | 2018 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2019 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir | 2019 |
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; CD4 Lymphocyte Count; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults
Topics: Adenine; Adult; Alanine; Amides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Pilot Projects; Piperazines; Prospective Studies; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2020 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Topics: Adenine; Amides; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Logistic Models; Multivariate Analysis; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir | 2020 |
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Topics: Alanine; Amides; Anti-HIV Agents; Drug Combinations; Drug Resistance; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; RNA; Tenofovir; United States; Viral Load | 2021 |
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Child; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir | 2023 |
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Biological Availability; Cross-Over Studies; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2022 |
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; RNA; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Injection Site Reaction; Male; Middle Aged; Rilpivirine; RNA; Tenofovir; Viral Load; Young Adult | 2023 |
46 other study(ies) available for tenofovir and bictegravir
Article | Year |
---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
CROI 2018: Advances in Antiretroviral Therapy.
Topics: Adenine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Congresses as Topic; Deoxyadenosines; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir; Viral Load | 2018 |
What did we learn from the bictegravir switch studies?
Topics: Adenine; Adult; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Protease Inhibitors; Pyridones; Tenofovir | 2018 |
Biktarvy--another INSTI-based combination for HIV.
Topics: Amides; Anti-HIV Agents; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2018 |
Drug updates and approvals: 2018 in review.
Topics: Adenine; Alanine; Amides; Aminophenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodioxoles; Clonidine; Doxylamine; Drug Approval; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Piperazines; Pyridones; Pyridoxine; Quinolones; Tenofovir; United States; United States Food and Drug Administration | 2018 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Mutation; Piperazines; Pyridones; Tenofovir; Toxoplasmosis, Cerebral; Treatment Failure | 2020 |
Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Emtricitabine; Gynecomastia; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2020 |
Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Amides; Anti-HIV Agents; Depression; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2020 |
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
Topics: Adenine; Aged; Alanine; Amides; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HEK293 Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Piperazines; Pyridones; Tenofovir; Treatment Failure | 2020 |
Weighing considerations with newer antiretrovirals.
Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2020 |
Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Deglutition; Drug Combinations; Emtricitabine; Female; Fruit and Vegetable Juices; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Piperazines; Pyridones; Solubility; Tenofovir | 2021 |
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Female; Genitalia; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Piperazines; Prospective Studies; Pyridones; Rectum; RNA; Tenofovir | 2021 |
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Macaca; Male; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir | 2021 |
[Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Topics: Adolescent; Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2021 |
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
Topics: Adenine; Adult; Alanine; Amides; Antiretroviral Therapy, Highly Active; BNT162 Vaccine; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Neutralization Tests; Piperazines; Pyridones; RNA, Viral; SARS-CoV-2; Tenofovir; Treatment Failure | 2021 |
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
Topics: Alanine; Amides; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Piperazines; Protease Inhibitors; Pyridones; Tacrolimus; Tenofovir | 2022 |
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Topics: Aged; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Cobicistat; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Tenofovir | 2021 |
Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2022 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Piperazines; Pyridones; Rifampin; Tenofovir | 2021 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Piperazines; Post-Exposure Prophylaxis; Pyridones; Tenofovir | 2022 |
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
Topics: Adult; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Piperazines; Pyridones; Retrospective Studies; Tenofovir | 2022 |
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Topics: Adult; Amides; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cohort Studies; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2022 |
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches.
Topics: Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Tenofovir | 2022 |
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Piperazines; Pyridones; Tenofovir | 2022 |
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA; Tenofovir | 2022 |
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer.
Topics: Amides; Anti-HIV Agents; Colorectal Neoplasms; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Integrase Inhibitors; Lamivudine; Piperazines; Pyridones; Raltegravir Potassium; Tenofovir | 2022 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir | 2021 |
Crushed vs dissolved bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Pyridones; Tenofovir | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Mutation; Retrospective Studies; Tenofovir; Viral Load | 2023 |
Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Anti-HIV Agents; Cell Differentiation; HIV Infections; Humans; Integrases; Mice; Raltegravir Potassium; Tenofovir | 2023 |
Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Patient Reported Outcome Measures; Quality of Life; Tenofovir; Treatment Outcome | 2023 |
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Topics: China; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Tenofovir | 2023 |
Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Tenofovir | 2023 |
[Sleep disorders related to HIV treatment.]
Topics: Adenine; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Pyridones; Sleep Wake Disorders; Spain; Tenofovir | 2023 |
A green approach for the analysis of emtricitabine bictegravir and tenofovir in a pharmaceutical preparation using novel HPLC and spectrophotometric methods.
Topics: Chromatography, High Pressure Liquid; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Pharmaceutical Preparations; Tenofovir | 2023 |
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir | 2023 |
Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |